Research
Hormonal
GLP-1 receptor agonists (Liraglutide, Semaglutide, Dulaglutide, Albiglutide, Efpeglenatide) significantly reduce MACE-3 and cardiovascular death in patients with Type 2 Diabetes and high cardiovascular risk.
If you have Type 2 Diabetes and high heart disease risk, GLP-1 agonists (injectable or oral) are recommended to reduce the risk of heart attack, stroke, and cardiovascular death. Discuss these options with your provider.
StrongSupportsVERY_HIGH confidence
Overall, GLP-1R agonists have proven to significantly improve CV outcomes in patients with T2DM... A meta-analysis of the above eight trials revealed a significant reduction in the MACE-3 end point compared to placebo by 14% (HR, 0.86; 95% CI, 0.79-0.94), which was for the most part driven by a reduction in CV mortality by 13%...
Why this rating
Multiple large RCTs (LEADER, SUSTAIN-6, REWIND, etc.) and meta-analyses support this.
Source
Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure
Khawaja M. Talha et al. · Methodist DeBakey Cardiovascular Journal · 2022
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →